Daiichi Sankyo’s DXd oncology platform offers substantial five-year upside, with ADC launches and pipeline expansion outweighing near-term margin, manufacturing, and regulatory execution risks.
Overview
Daiichi Sankyo is transitioning from a legacy cardiovascular and generic medicines company into a specialized oncology leader built around its proprietary DXd ADC platform. ENHERTU and DATROWAY are the commercial anchors, supported by Lixiana, Tarlige, regional businesses, and American Regent, while AstraZeneca and Merck partnerships extend development and global commercialization. **Underlying demand remains strong:** Q1 FY2026 revenue rose 21.1% year over year to JPY 574.7 billion, led by ENHERTU revenue growth of 48.9% to JPY 239.8 billion and DATROWAY growth of 176.4% to JPY 23.9 billion. However, core operating profit rose only 6.2% to JPY 107.3 billion, reported operating profit fell 12.0% to JPY 85.1 billion, and net income declined 19.7% to JPY 68.6 billion because of European restructuring, quality adjustments, profit-sharing, and higher costs. FY2026 revenue guidance was raised to JPY 2.34 trillion and operating profit guidance to JPY 320.0 billion. The stock fell 11.13% to JPY 2,567.50 after results, but at the report’s JPY 2,751.00 reference price, the scenario-weighted FY2030 target is JPY 6,262.89. Near-term catalysts include HER3-DXd manufacturing resolution, ENHERTU approvals, DESTINY-Lung04, and cost optimization.